# Phase 1 Study of PTX-100 in Patients With Advanced Malignancies With PTCL Expansion Cohort

> **NCT03900442** · PHASE1 · COMPLETED · sponsor: **Prescient Therapeutics, Ltd.** · enrollment: 25 (actual)

## Conditions studied

- Advanced Cancer
- PTCL

## Interventions

- **DRUG:** PTX-100

## Key facts

- **NCT ID:** NCT03900442
- **Lead sponsor:** Prescient Therapeutics, Ltd.
- **Sponsor class:** INDUSTRY
- **Phase:** PHASE1
- **Study type:** INTERVENTIONAL
- **Status:** COMPLETED
- **Start date:** 2019-09-01
- **Primary completion:** 2025-07-31
- **Final completion:** 2025-08-08
- **Target enrollment:** 25 (ACTUAL)
- **Last updated:** 2025-09-02


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT03900442

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT03900442, "Phase 1 Study of PTX-100 in Patients With Advanced Malignancies With PTCL Expansion Cohort". Retrieved via AI Analytics 2026-06-02 from https://api.ai-analytics.org/clinical/NCT03900442. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*